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Efficacy of Combination of Immunotherapies in a Murine in a Murine Squamous Cell Carcinoma 
Model 
 
Introduction: Head and neck squamous cell carcinomas (HNSCCs) are a type of neoplasm found 
in the epithelium of the oral cavity, oropharynx, nasopharynx, larynx, or hypopharynx. Recent 
evidence has demonstrated that 70-90% of HNSCC are associated with Human Papillomavirus 
(HPV), particularly strain 16 producing oncogenic proteins E6/E7. 1 Currently, HNSCCs are treated 
with surgery, chemotherapy, and radiation, however immunotherapy with immune checkpoint 
(PD-1) blocking agents promises to improve outcomes in HNSCC.2  
Objective: This study examined the therapeutic effects of dual and triple combination 
immunotherapies in a mouse model of HPV-associated HNSCC.  
Methods: Treatment modalities included a tumor vaccine (attenuated Listeria monocytogenes 
based vaccine encoding HPV16 E6/E7 (AXAL)), an immune checkpoint inhibitor targeting PD1 
(RMP1-14) and topical subtherapeutic radiation. Mice were injected subcutaneously with tumor 
cells expressing HPV16 E6/E7 (TC-1). When tumors were established, mice were vaccinated with 
AXAL (3 injections) either alone and/or with anti-PDi and/or with a single dose of radiation. 
Results: Partial responses were observed in some mice receiving dual combination therapies. 
Most mice treated with triple immunotherapy revealed complete tumor regression. 
Discussion: Combination immunotherapy is effective in the TC-1 HNSCC model system. The 
results obtained set the stage for investing immune mechanism underpinning treatment-
associated tumor regression. 
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